The impact of various breast-cancer treatments on patients with a BRCA2 mutation has not been studied. We sought to estimate the impact of bilateral oophorectomy and other treatments on breast cancer-specific survival among patients with a germline BRCA2 mutation.
We identified 664 women with stage I–III breast cancer and a BRCA2 mutation by combining five different datasets (retrospective and prospective). Subjects were followed for 7.2 years from diagnosis to death from breast cancer. Tumour characteristics and cancer treatments were patient-reported and derived from medical records. Predictors of survival were determined using Cox proportional hazard models, adjusted for other treatments and for prognostic features.
The 10-year breast-cancer survival for ER-positive patients was 78.9% and for ER-negative patients was 82.3% (adjusted HR = 1.23 (95% CI, 0.62–2.45, p = 0.55)). The 10-year breast-cancer survival for women who had a bilateral oophorectomy was 89.1% and for women who did not have an oophorectomy was 59.0% (adjusted HR = 0.45; 95% CI, 0.28–0.72, p = 0.001). The adjusted hazard ratio for chemotherapy was 0.83 (95% CI, 0.65–1.53: p = 0.56).
For women with breast cancer and a germline BRCA2 mutation, positive ER status does not predict superior survival. Oophorectomy is associated with a reduced risk of death from breast cancer and should be considered in the treatment plan.
Subscribe to Journal
Get full journal access for 1 year
only $16.63 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Byrski, T., Gronwald, J., Huzarski, T., Grzybowska, E., Budryk, M., Stawicka, M. et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J. Clin. Oncol. 28, 375–379 (2010).
Narod, S. A., Huzarski, T., Gronwald, J., Byrski, T., Marczyk, E., Cybulski, C. et al. Predictors of survival for breast cancer patients with a BRCA1 mutation. Breast Cancer Res. Treat. 168, 513–521 (2018).
Metcalfe, K., Lynch, H. T., Foulkes, W. D., Tung, N., Kim-Sing, C., Olopade, O. I. et al. Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers. JAMA Oncol. 1, 306–313 (2015).
Metcalfe, K., Gershman, S., Ghadirian, P., Lynch, H. T., Snyder, C., Tung, N. et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ 348, g226 (2014).
Jayasekara, H., MacInnis, R. J., Chamberlain, J. A., Dite, G. S., Leoce, N. M., Dowty, J. G. et al. Mortality after breast cancer as a function of time since diagnosis by estrogen receptor status and age at diagnosis. Int. J. Cancer 145, 3207–3217 (2019).
Jonasson, J. G., Stefansson, O. A., Johannsson, O. T., Sigurdsson, H., Agnarsson, B. A., Olafsdottir, G. H. et al. Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers. Br. J. Cancer 115, 776–783 (2016).
Metcalfe, K., Lynch, H. T., Foulkes, W. D., Tung, N., Olopade, O. I., Eisen, A. et al. Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. Br. J. Cancer 120, 398–403 (2019).
Shuster, L. T., Gostout, B. S., Grossardt, B. R. & Rocca, W. A. Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int. 14, 111–116 (2008).
Cybulski, C., Kluźniak, W., Huzarski, T., Wokołorczyk, D., Kashyap, A., Rusak, B. et al. The spectrum of mutations predisposing to familial breast cancer in Poland. Int. J. Cancer 145, 3311–3320 (2019).
Mann, G. J., Thorne, H., Balleine, R. L., Butow, P. N., Clarke, C. L., Edkins, E. et al. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res. 8, R12 (2006).
Phillips, K. A., Butow, P. N., Stewart, A. E., Chang, J. H., Weideman, P. C., Price, M. A. et al. Predictors of participation in clinical and psychosocial follow-up of the kConFab Breast Cancer Family Cohort. Fam. Cancer 4, 105–113 (2005).
Phillips, K. A., Milne, R. L., Buys, S., Friedlander, M. L., Ward, J. H., McCredie, M. et al. Agreement between self-reported breast cancer treatment and medical records in a population-based breast cancer family registry. J. Clin. Oncol. 23, 4679–4686 (2005).
Foulkes, W. D., Metcalfe, K., Sun, P., Hanna, W. M., Lynch, H. T., Ghadirian, P. et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin. Cancer Res. 10, 029–2034 (2004).
Olafsdottir, E., Borg, A., Jensen, M. B., Gerdes, A. M., Johansson, A. L. V., Barkardottir, R. B. et al. Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status. Br. J. Cancer https://doi.org/10.1038/s41416-020-01056-4 (2020).
Bane, A. L., Beck, J. C., Bleiweiss, I., Buys, S. S., Catalano, E., Daly, M. B. et al. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am. J. Surg. Pathol. 31, 121–128 (2007).
Goodwin, P. J., Phillips, K. A., West, D. W., Ennis, M., Hopper, J. L., John, E. M. et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. J. Clin. Oncol. 30, 19–26 (2012).
Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Colleoni, M., Láng, I. et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N. Engl. J. Med. 379, 122–137 (2018).
Our sincere gratitude for the valuable contributions of the women who participated in this study, without whom this research would not be possible. We would like to acknowledge the following individuals for helping with data collection: Sara Lazzarin, Debora Vicini and Federica Sina.
Other members of the Polish Hereditary Breast Cancer Consortium
Błasińska-Morawiec Maria16, Chosia Maria17, Drosik Kazimierz18, Gozdecka-Grodecka Sylwia19, Goźdź Stanisław20, Grzybowska Ewa21, Jeziorski Arkadiusz22, Karczewska Aldona23, Kordek Radzisław22, Synowiec Agnieszka24, Kozak-Klonowska Beata25, Lamperska Katarzyna26, Lange Dariusz27, Mackiewicz Andrzej19, Mituś Jerzy Władysław28, Niepsuj Stanislas29, Oszurek Oleg17, Gugała Karol30, Morawiec Zbigniew16, Mierzwa Tomasz31, Posmyk Michał32, Ryś Janusz33, Szczylik Cezary34, Uciński Michał17, Urbański Krzysztof35, Waśko Bernard36, Wandzel Piotr37
Other members of the kConFab Follow-Up Study Team
Michael Friedlander38, Sue Anne McLachlan39, Stephanie Nesci40, Sandra Picken40, Sarah O’Connor40, Lucy Stanhope40
Other members of Hereditary Breast Cancer Clinical Study Group
Andrea Eisen41, Kevin Sweet42, Raymond Kim43, William Foulkes44, Pal Moller45, Susan Neuhausen46, Carey Cullinane47, Charis Eng48, Peter Ainsworth49, Fergus Couch50, Christian Singer51, Beth Karlan52, Wendy McKinnon53, Marie Wood53
Ethics approval and consent to participate
The study was approved by the following institutional ethics review boards: Women’s College Hospital Ethics Board, Research Ethics Committee of the Pomeranian Medical University, Central Manchester Research Ethics Committee (10/H1008/24 and 11/H1003/3), Peter MacCallum Cancer Centre Human Research Ethics Committee (97/27) and the Ethical Committee Brianza. All study subjects provided written informed consent. The study was performed in accordance with the Declaration of Helsinki.
Consent to publish
Individual person’s data not included.
All data relevant to the study are included in the paper.
Steven A. Narod is a board member of BJC. All other authors declare no conflict of interest.
This work was supported by grants to kConFab and the kConFab Follow-Up Study from Cancer Australia (809195, 1100868), the Australian National Breast Cancer Foundation (IF 17), the National Health and Medical Research Council (454508, 288704 and 145684), the National Institute of Health USA (1RO1CA159868), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia and the Cancer Foundation of Western Australia. K.A.P. is an Australian National Breast Cancer Foundation Fellow (PRAC17-004). The work is supported by the Peter Gilgan Center for Research on Women’s Cancers and the Canadian Institute of Health Research (FDN 154275). D.G.E. is supported by the NIHR Manchester Biomedical Research Centre (IS-BRC-1215-20007).
Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Members of the Polish Breast Cancer Consortium, kConFab Follow-Up Study Team and Hereditary Breast Cancer Clinical Study Group are listed above Acknowledgements.
About this article
Cite this article
Evans, D.G., Phillips, KA., Milne, R.L. et al. Survival from breast cancer in women with a BRCA2 mutation by treatment. Br J Cancer 124, 1524–1532 (2021). https://doi.org/10.1038/s41416-020-01164-1